Detection of Mutant p53 Protein in Ovarian Cancer
Author Information
Author(s): J. Renninson, B.W. Baker, A.T. McGown, D. Murphy, J.D. Norton, B.W. Fox, D. Crowther
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital NHS Trust
Hypothesis
Is there a correlation between mutant p53 protein presence and clinicopathological features in ovarian adenocarcinoma?
Conclusion
The study found a significant difference in p53 positivity between serous and mucinous ovarian tumors, but no correlation with treatment response or differentiation stage.
Supporting Evidence
- 56% of the ovarian adenocarcinoma cases examined were p53 positive.
- 18 out of 23 serous tumors were p53 positive compared to 3 out of 12 mucinous tumors.
- There was no significant correlation between p53 status and differentiation stage or response to treatment.
Takeaway
The study looked at 50 ovarian cancer samples to see if a specific protein, p53, was present and found that it was more common in one type of tumor than another.
Methodology
The study used immunohistochemical staining and direct nucleotide sequencing to analyze p53 expression in tumor samples.
Limitations
The study had a small number of early-stage cases, limiting the ability to draw conclusions about p53 status in those stages.
Participant Demographics
Patients undergoing laparotomy for epithelial ovarian cancer in the north-west of England.
Statistical Information
P-Value
0.0237
Statistical Significance
p=0.0237
Want to read the original?
Access the complete publication on the publisher's website